The global diabetes care devices market was valued at USD 33.58 billion in 2024, projected to grow to USD 36.45 billion in 2025, and is expected to reach USD 76.44 billion by 2034 at a CAGR of 8.54% (2025–2034).
Download the free sample and get the complete insights and forecasts report on this market @ https://www.towardshealthcare.com/download-sample/5605
North America dominated in 2024 due to high diabetes prevalence and advanced healthcare adoption, while Europe is projected to grow at the fastest rate. By monitoring devices, glucometers held the largest share in 2024, while continuous glucose monitoring (CGM) devices are forecast to grow at the fastest CAGR. In management devices, disposable insulin pens led in 2024, but insulin pumps are expected to grow the fastest.
◉2024 Market Size – USD 33.58 billion.
◉2025 Market Size – USD 36.45 billion.
◉2034 Projected Market Size – USD 76.44 billion.
◉CAGR (2025–2034): 8.54%.
◉North America – Largest share due to advanced infrastructure and patient adoption.
◉Europe – Fastest growth due to awareness and healthcare investment.
◉Asia-Pacific – Significant growth driven by diabetes prevalence in India & China.
◉Glucometer devices – Largest segment.
◉Continuous Glucose Monitoring devices – Fastest-growing.
◉Disposable insulin pens – Largest share.
◉Insulin pumps – Highest CAGR due to smart integration.
◉In Dec 2023, Tandem Diabetes Care launched Tandem Source Management Platform, enhancing data reporting & centralized patient monitoring.
◉In Mar 2025, Tandem launched Control-IQ+ hybrid closed-loop technology in the U.S. for both Type 1 & Type 2 diabetes.
◉In Oct 2024, Glooko raised $100 million to expand its diabetes management solutions across North America, Middle East, and Asia.
Collaboration for Innovation
◉In Jan 2025, Tandem Diabetes Care collaborated with the University of Virginia (UVA) to develop a fully automated closed-loop insulin system.
◉In Oct 2023, Dr. Reddy’s launched Celevida Wellness in India, offering digital access to diabetes management solutions.
Partnerships for Competitive Edge
◉In Aug 2024, Medtronic partnered with Abbott to integrate glucose monitoring technologies into insulin delivery systems.
◉AI enables prediction of glucose fluctuations by analyzing continuous patient data. This reduces risks of hypoglycemia and hyperglycemia.
◉AI-powered insulin pumps and smart pens use adaptive algorithms to calculate insulin needs in real-time, offering personalized therapy.
◉AI integrates with cloud platforms & apps for physicians to monitor patient health remotely, ensuring early interventions.
◉AI tools provide clinicians with data-driven insights to optimize therapy adjustments and improve long-term outcomes.
◉Smartwatches & CGMs embedded with AI track lifestyle patterns and adjust diabetes management accordingly.
◉By reducing hospitalizations through proactive monitoring, AI lowers overall diabetes care costs.
Prevalence: 136 million U.S. adults affected by diabetes/prediabetes (CDC 2023).
Drivers: FDA approvals, reimbursement policies, and high adoption of CGMs & pumps.
Canada: Over 5.7M diagnosed; government subsidies like Pharmacare Act ensure device access.
UK: NHS adoption of hybrid closed-loop systems boosts CGM and pump usage.
Germany: 8.5M diabetics (2024) projected to reach 12M by 2040; strong push for telemedicine & mHealth apps.
EU Initiatives: Programs like Horizon Europe advance diabetes research & device adoption.
China: Largest diabetic population globally; government-backed Metabolic Management Centers push access to devices.
India: 101M diabetics; growing presence of local/global device makers and telemedicine adoption.
Japan & Korea: Rapid adoption of CGMs and digital health apps.
Growing awareness in Brazil & Mexico, but adoption limited by affordability.
Increasing penetration of smart insulin pens and low-cost glucometers.
Saudi Arabia & UAE: Rising diabetes prevalence due to lifestyle changes.
South Africa: Limited access but government programs improving affordability.
Regulatory frameworks are playing a central role in shaping the diabetes care devices market. While stricter compliance requirements increase development costs and approval timelines, they also drive safer, evidence-based innovations and open the path for broader reimbursement and adoption.
Stricter European Regulations (EU MDR)
◉Devices must meet higher standards for clinical evidence, safety, post-market surveillance, and technical documentation.
◉This has slowed product launches but ensures safer technologies with stronger market credibility.
U.S. FDA Evolving Approach
◉The FDA has introduced clear pathways for continuous glucose monitors, interoperable insulin pumps, and automated insulin delivery systems.
◉Component-based approvals allow sensors, algorithms, and delivery hardware to be validated independently, encouraging modular and interoperable solutions.
Oversight of Digital Health, AI, and Software-as-a-Medical-Device
◉Regulators are establishing stricter rules for algorithm validation, explainability, and data governance.
◉This ensures AI-driven dosing or predictive tools meet transparency and safety standards before wide adoption.
Emerging Market Regulations
◉Countries like India have expanded medical device rules, classifying more diabetes devices under central regulatory control.
◉This creates predictable approval pathways and strengthens safety oversight in growing markets.
Lifecycle and Post-Market Surveillance Requirements
◉Regulations now emphasize real-world evidence, ongoing safety reporting, and cybersecurity updates for connected devices.
◉This shifts compliance from a one-time hurdle to a continuous responsibility.
Development and Time-to-Market
◉Companies face longer timelines and higher costs due to increased evidence and validation requirements.
◉Smaller firms are pressured to partner with larger players or risk being pushed out by compliance demands.
Technology and Innovation
◉Interoperability has become a regulatory priority, steering manufacturers toward open platforms rather than closed systems.
◉AI-driven features must meet rigorous validation standards, influencing how algorithms are designed and updated.
Commercial and Reimbursement Dynamics
◉Regulatory approvals expanding device use from Type 1 to Type 2 diabetes significantly increase the addressable market.
◉Stronger evidence requirements enhance payer confidence, accelerating reimbursement adoption.
Post-Market Compliance
◉Companies must invest in systems for real-world data collection, cybersecurity monitoring, and ongoing clinical performance reporting.
◉This raises operational costs but improves safety, trust, and long-term device reliability.
Europe: EU MDR favors well-resourced companies capable of absorbing compliance costs, consolidating market share among major players.
United States: FDA’s modular approach accelerates innovation, particularly in automated insulin delivery and interoperable ecosystems.
Asia-Pacific (e.g., India): Strengthening regulations create opportunities for global players to expand, but local firms must scale compliance capabilities to stay competitive.
◉Established players gain an advantage, as they have the resources to meet stricter regulations and generate the required clinical evidence.
◉Startups and smaller manufacturers face higher entry barriers but can thrive if they specialize in interoperable components or niche innovations.
◉The emphasis on cybersecurity, post-market monitoring, and AI transparency ensures long-term growth by fostering patient trust and payer acceptance.
Short Term: Rising compliance costs, delayed product launches, and consolidation within the market.
Medium to Long Term: Stronger evidence-backed products, wider reimbursement coverage, broader patient eligibility (including Type 2 approvals), and accelerated adoption of interoperable systems.
◉Rising Prevalence of Diabetes – IDF reports 537M adults in 2023, projected to reach 783M by 2045.
◉Technological Advancements – Hybrid closed-loop systems, AI-driven CGMs, and smart pens.
◉Lack of Awareness & Education – Low adoption of CGMs & pumps in underdeveloped regions.
◉Affordability Issues – High cost limits penetration in low-income countries.
◉Government Initiatives – WHO’s Global Diabetes Compact, EU’s Horizon Europe, and U.S. National Diabetes Prevention Program.
◉E-commerce Growth – Direct-to-consumer platforms like Celevida Wellness in India expand access.
Products: Insulin pumps, CGMs.
Strength: Global presence, strong R&D, strategic partnerships (Abbott).
Products: Freestyle Libre CGM systems.
Strength: Market leader in CGM, user-friendly wearable devices.
Products: Dexcom G7 CGM.
Strength: High accuracy sensors, expanding reimbursement coverage.
Products: Glucose monitoring systems, insulin delivery systems.
2024 Sales: CHF 60.495M.
Strength: Strong diagnostics portfolio, digital integration.
Products: Test strips, lancets, CGM systems.
2024 Sales: €46.6B.
Strength: Established global brand, wide product coverage.
Products: Omnipod insulin management system.
Strength: Non-invasive, tubeless insulin delivery.
Products: Insulin pens, digital connected devices.
Strength: Leader in insulin therapies and global penetration.
◉What: Rollout of Control-IQ+, an upgraded hybrid closed-loop insulin delivery algorithm.
◉Target Users: Type 1 diabetics aged 2+ and adults with Type 2 diabetes.
Key Features:
◉Greater personalization & flexibility in insulin dosing.
◉Integrated with t:slim X2 Insulin Pump and Tandem Mobi System.
◉Remote software updates available for existing users → lower upgrade barriers.
Impact: Expands patient base (previously only Type 1), strengthens Tandem’s competitive edge vs. Medtronic and Insulet.
◉What: First FDA clearance of a closed-loop AID system for Type 2 diabetes.
Importance:
◉Broadens applicability beyond insulin-intensive Type 1 patients.
◉Sets regulatory precedent for other companies developing Type 2-focused insulin automation.
◉Strategic Impact: Enhances adoption in the largest diabetic segment globally (Type 2 diabetes ~90–95% of cases).
◉Purpose: Scale diabetes data management platform.
◉Expansion Regions: North America, Middle East, Asia.
Focus Areas:
◉Enhancing patient-provider connectivity.
◉Broader device integration (glucometers, CGMs, insulin pens).
◉AI-driven analytics for predictive diabetes care.
Impact: Positions Glooko as a global digital health leader, supporting both device makers & patients.
◉What: Strategic partnership between Medtronic (insulin pumps) and Abbott (Freestyle Libre CGMs).
◉Objective: Integrate Abbott’s sensor technology into Medtronic’s insulin delivery systems.
Strategic Importance:
◉Addresses Medtronic’s underperforming diabetes unit.
◉Enhances patient choice with hybrid closed-loop ecosystems.
◉Creates competitive pressure on Dexcom-Tandem and Insulet alliances.
◉What: A cloud-based diabetes management platform consolidating data from insulin pumps & CGMs.
Features:
◉Advanced analytics & patient trend reports.
◉Unified data access for clinicians & patients.
◉Impact: Improves treatment personalization & adherence.
◉Objective: Co-develop a fully automated closed-loop insulin system (no manual input required).
Partnership Synergy:
◉UVA: Pioneering AI-driven algorithms.
◉Tandem: Expertise in insulin delivery hardware/software.
◉Future Impact: Expected to push next-gen “artificial pancreas” systems into mainstream use.
◉What: Direct-to-consumer e-commerce platform for diabetes products.
Drivers:
◉India’s diabetic population (~101 million).
◉Rising demand in Tier 2 & Tier 3 cities.
◉Offerings: Nutrition, digital tools, and diabetes-friendly products.
◉Impact: Expands accessibility & affordability in emerging markets.
a. Self-Monitoring Blood Glucose (SMBG) Devices
◉Includes: Glucometers, test strips, lancets.
◉Market Status (2024): Largest share due to affordability & wide adoption.
◉Advantages: Portable, quick results, relatively low cost.
◉Limitations: Snapshot readings only (no continuous monitoring).
b. Continuous Glucose Monitoring (CGM) Devices
◉Includes: Sensors, transmitters, receivers.
◉Growth Outlook: Fastest CAGR segment due to demand for real-time tracking.
Advantages:
◉24/7 glucose trends & alerts.
◉Integration with pumps → automated insulin delivery.
◉Drivers: Adoption of wearables, improved sensor accuracy, reimbursement coverage.
a. Insulin Pumps
◉Types: Reservoirs, infusion sets, monitors.
◉CAGR: Highest growth due to automation & precision dosing.
◉Key Feature: Works seamlessly with CGMs (closed-loop).
b. Insulin Pens
◉Disposable Pens:
◉Largest market share in 2024.
◉Prefilled, portable, and user-friendly.
◉Popular in emerging markets due to low training needs.
Reusable Pens (Cartridges):
◉Growing slowly, cost-effective long-term.
c. Others
◉Insulin Syringes: Traditional, still widely used in developing markets.
◉Jet Injectors: Needle-free but niche adoption.
◉AI-Powered Glucose Prediction Models
◉Example: NIT Rourkela’s 2025 AI system predicts glucose levels with higher accuracy → helps preempt hypoglycemia/hyperglycemia.
◉Trend: Moving from reactive treatment → preventive insulin adjustment.
Decision Support Systems (DSS):
◉Platforms like Glooko and Tandem Source use AI + analytics to recommend therapy adjustments.
◉Impact: Enhances clinical workflows, reduces HCP burden.
Hybrid Closed-Loop (HCL) Systems:
◉Already commercial (e.g., Tandem Control-IQ+, Medtronic 780G).
◉Disruption: Gradually replacing manual insulin therapy with semi-autonomous insulin dosing.
Fully Automated Closed-Loop Systems:
◉Next frontier → requires zero manual input.
◉Example: Tandem + UVA project (2025) for a truly artificial pancreas.
◉Impact: Eliminates human dosing errors, improves quality of life.
Factory-Calibrated Sensors:
◉Abbott’s Freestyle Libre and Dexcom G7 → no fingerstick calibration.
Wearable & Long-Lasting Sensors:
◉Extended sensor lifespans (14–180 days) → fewer replacements.
Implantable CGMs:
◉Senseonics’ Eversense lasts up to 180 days → disruptive for compliance.
◉Trend: Integration of CGMs with smartphones, watches, and insulin pumps.
Smart Pens (Novo Nordisk, Lilly, Companion Medical):
◉Bluetooth-enabled pens → track dose, timing, and sync with apps.
◉Reduces missed doses & overdosing.
Connectivity Integration:
◉Smart pens now connect to CGMs → giving holistic patient insights.
◉Impact: Bridges gap for patients not ready for full insulin pumps.
Smartwatches & Health Platforms:
◉Apple, Fitbit, Samsung integrating glucose monitoring into wearables.
◉Trend: Moving towards non-invasive glucose monitoring (optical sensors, sweat analysis).
IoT-Enabled Devices:
◉Pumps, pens, and CGMs connected via cloud platforms (Tandem Source, Glooko).
◉Impact: Remote patient monitoring & telemedicine acceleration.
◉Tandem Mobi Pump (smallest tubed pump): Disrupts usability by being discreet & wearable.
◉Patch Pumps (Insulet Omnipod): Tubeless design improving comfort & mobility.
◉Design Shift: From bulky, clinic-based devices → consumer-friendly, lifestyle devices.
◉Unified Diabetes Management Platforms:
◉Tandem Source, Glooko, mySugr → centralize SMBG, CGM, pump, and pen data.
EHR & Telemedicine Integration:
◉Seamless sharing of patient data with providers.
◉Disruption: Makes diabetes care continuous, personalized, and remotely accessible.
◉Genomics & AI-Powered Algorithms: Tailored insulin dosing based on patient-specific metabolic patterns.
◉Personalized Nutrition & Lifestyle Apps: Integrated into device ecosystems.
◉Impact: Shifts from one-size-fits-all to individualized diabetes therapy.
Tech Approaches Under Development:
◉Optical spectroscopy (infrared light).
◉Sweat, saliva, tear glucose sensors.
◉Potential Impact: If successful, could phase out fingersticks & implantable CGMs.
◉Current Status: Early-stage R&D, but Apple, Google, and startups are pushing.
◉Massive Patient Data Pools: CGMs & pumps generate real-time data.
◉Predictive Insights: Helps forecast insulin resistance, complications, and hospitalizations.
◉Healthcare Provider Benefit: Early intervention → reduced hospitalization costs.
◉Drivers: High diabetes prevalence (136M adults diabetic/prediabetic in U.S.), advanced R&D, reimbursement policies.
◉Canada: Expanding with subsidies & Pharmacare Act.
◉UK: NHS support for hybrid closed-loop systems.
◉Germany: 8.5M diabetics, expected to hit 12M by 2040; strong digital health adoption.
EU-Wide: Horizon Europe supporting diabetes tech innovation.
◉China: World’s largest diabetic population; government’s Metabolic Management Centers expand access.
◉India: 101M diabetics, push for telemedicine & digital health in rural areas.
◉Japan/Korea: Rapid CGM adoption due to aging population & tech-savvy patients.
◉Brazil: Growing awareness but affordability barriers.
◉Mexico: Rising obesity & diabetes prevalence driving demand.
◉Saudi/UAE: Lifestyle-driven diabetes surge; strong investment in healthcare modernization.
◉South Africa: Low access but improving via government initiatives.
Q1. What is the size of the global diabetes care devices market?
The market was USD 33.58 billion in 2024, projected to reach USD 76.44 billion by 2034 at a CAGR of 8.54%.
Q2. Which region leads the diabetes care devices market?
North America dominated in 2024, but Europe is expected to grow the fastest during the forecast period.
Q3. Which device segment dominated in 2024?
Monitoring devices: Glucometers held the largest share.
Management devices: Disposable insulin pens dominated.
Q4. Which device type will grow the fastest?
CGMs (Continuous Glucose Monitors) in monitoring devices.
Insulin Pumps in management devices.
Q5. What role does AI play in diabetes care devices?
AI enables predictive glucose monitoring, personalized insulin dosing, remote patient monitoring, and clinical decision support, making diabetes care proactive and data-driven.
Check out the details below
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5605
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
The global nootropics market size reached USD 5.71 billion in 2025 and is projected to grow to USD 19.53 billion… Read More
The U.S. concierge medicine market was valued at USD 7.25 billion in 2024, grew to USD 8 billion in 2025,… Read More
The global recombinant proteins market is valued at USD 3.36 billion in 2025 and projected to reach USD 8.08 billion… Read More
The global digital biomarkers market was valued at USD 5.09 billion in 2025 and is projected to reach USD 32.37… Read More
The global chemotherapy market is estimated at USD 10.28 billion in 2025 and projected to reach USD 19.35 billion by… Read More
The global endoscopy devices market was valued at USD 61.1 billion in 2024, increased to USD 63.44 billion in 2025,… Read More